Biofourmis, founded in 2015 and headquartered in Boston, Massachusetts, has raised a total of $463.6 million across nine funding rounds, reaching a valuation of at least $1 billion as of April 2022. The company’s funding journey includes a $35 million Series B in 2019, a $100 million Series C led by SoftBank Vision Fund in 2020, and a $300 million Series D led by General Atlantic in April 2022, followed by a $20 million extension from Intel Capital in July 2022. Biofourmis uses AI-driven health analytics and digital therapeutics to power virtual care globally.